Literature DB >> 10566554

Reproductive and hormonal risk factors for thyroid cancer in Los Angeles County females.

W J Mack1, S Preston-Martin, L Bernstein, D Qian, M Xiang.   

Abstract

We conducted an individually matched case-control study (292 pairs) of female thyroid cancer patients to examine the role of reproductive history and exogenous hormones in this disease. Radiation treatment to the head or neck [28 cases and 2 controls exposed; odds ratio (OR), 14.0; 95% confidence interval (CI), 3.5-121.3] and certain benign thyroid diseases (including adolescent thyroid enlargement, goiter, and nodules or tumors) were strongly associated with thyroid cancer. Irregular menstruation increased risk (OR, 1.8; 95% CI, 0.9-3.7). Age at menarche and pregnancy history were not related to disease. Women with natural menopause and hysterectomized women without oophorectomy had no increase in risk, but disease risk was elevated in women with bilateral oophorectomy (OR, 6.5; 95% CI, 1.1-38.1). In general, use of oral contraceptives and other exogenous estrogens was not associated with thyroid cancer. However, risk increased with number of pregnancies in women using lactation suppressants (P = 0.03) and decreased with duration of breastfeeding (P = 0.04). These data provide only limited support for the hypothesis that reproductive and hormonal exposures are responsible for the marked excess of thyroid cancer risk in adult females.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10566554

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  30 in total

1.  Risk factors of thyroid cancer in Babol, Northern Iran.

Authors:  Zoleika Moazezi; Mahmoud Mahmoudi; Yousef Yahyahpour; Alireza Alaleh
Journal:  Caspian J Intern Med       Date:  2011

2.  Role of GST and NAT2 polymorphisms in thyroid cancer.

Authors:  A Hernández; N Xamena; J Surrallés; P Galofré; A Velázquez; A Creus; R Marcos
Journal:  J Endocrinol Invest       Date:  2008-11       Impact factor: 4.256

3.  Comparison of exposures among Arab American and non-Hispanic White female thyroid cancer cases in metropolitan Detroit.

Authors:  L Peterson; A Soliman; J J Ruterbusch; N Smith; K Schwartz
Journal:  J Immigr Minor Health       Date:  2011-12

4.  Role of goiter and of menstrual and reproductive factors in thyroid cancer: a population-based case-control study in New Caledonia (South Pacific), a very high incidence area.

Authors:  Thérèse Truong; Laurent Orsi; Dominique Dubourdieu; Yannick Rougier; Denis Hémon; Pascal Guénel
Journal:  Am J Epidemiol       Date:  2005-06-01       Impact factor: 4.897

5.  Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006.

Authors:  Tsogzolmaa Dorjgochoo; Xiao-Ou Shu; Hong-Lan Li; Han-Zhu Qian; Gong Yang; Hui Cai; Yu-Tang Gao; Wei Zheng
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

Review 6.  New insights in risk stratification of differentiated thyroid cancer.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

7.  Hysterectomy, Oophorectomy, and Risk of Thyroid Cancer.

Authors:  Juhua Luo; Michael Hendryx; JoAnn E Manson; XiaoYun Liang; Karen L Margolis
Journal:  J Clin Endocrinol Metab       Date:  2016-07-26       Impact factor: 5.958

Review 8.  Modeling thyroid cancer in the mouse.

Authors:  X-G Zhu; S-Y Cheng
Journal:  Horm Metab Res       Date:  2009-04-08       Impact factor: 2.936

Review 9.  Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).

Authors:  Carmelo Nucera; Melanie Goldfarb; Richard Hodin; Sareh Parangi
Journal:  Biochim Biophys Acta       Date:  2009-01-31

10.  Breastfeeding and thyroid cancer risk in women: A dose-response meta-analysis of epidemiological studies.

Authors:  Xingyang Yi; Jingjing Zhu; Xiao Zhu; Guang Jian Liu; Lang Wu
Journal:  Clin Nutr       Date:  2015-12-17       Impact factor: 7.324

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.